Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine

Executive Summary

FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.

You may also be interested in...



Sanofi Consumer Sales Slow As Pandemic-Driven Surge Ends, But OTC Xyzal Line Still Shines

Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.

OTC Xyzal Sales Jump Helps Drive Sanofi Consumer Health Q2 Sales

French pharma reports OTC Xyzal sales up nearly 86% to $14.5m during latest quarter, providing driver for allergy/cough/cold segment of its consumer health business. Total consumer health revenues, including nutritional and personal care products, up 1.1% at a consent exchange rate to $1.3bn during the April-June period.

Sanofi Xyzal OTC Antihistamine Claims Lose Second Challenge In Six Months

Sanofi will modify claims in social media ads that its Xyzal Allergy 24HR antihistamine is 'twice as fast' as Bayer's s Claritin after the US National Advertising Division found the statement is not supported by head-to-head testing. NAD also recommended the firm discontinue the claim the product provides “relief that starts at hour 1 instead of hour 2.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel